Fine particulate air pollution <2.5 μm in diameter (PM 2.5 ) is a major environmental threat to global public health. Multiple national and international medical and governmental organizations have recognized PM 2.5 as a risk factor for cardiopulmonary diseases. A growing body of evidence indicates that several personal-level approaches that reduce exposures to PM 2.5 can lead to improvements in health endpoints. Novel and forward-thinking strategies including randomized clinical trials are important to validate key aspects (e.g., feasibility, efficacy, health benefits, risks, burden, costs) of the various protective interventions, in particular among real-world susceptible and vulnerable populations. This paper summarizes the discussions and conclusions from an expert workshop, Reducing the Cardiopulmonary Impact of Particulate Matter Air Pollution in High Risk Populations, held on May 29 to 30, 2019, and convened by the National Institutes of Health, the U.S. Environmental Protection Agency, and the U.S. Centers for Disease Control and Prevention., Competing Interests: Author Disclosures The views expressed in this paper are those of the authors and do not necessarily represent the views of the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), National Institute of Environmental Health Sciences, Environmental Protection Agency, Centers for Disease Control and Prevention, or the United States Department of Health and Human Services. Drs. Bhatt and Brooks served as co-chairs of this NIH/NHLBI/EPA/CDC Expert Workshop on air pollution. Dr. Newman has received grant support from the NIH (K23HL125991). Dr. Bhatt has served on the advisory board of Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Level Ex, Medscape Cardiology, PhaseBio, PLx Pharma, and Regado Biosciences; has served on the Board of Directors for Boston VA Research Institute, Society of Cardiovascular Patient Care, and TobeSoft; has served as chair of the American Heart Association Quality Oversight Committee, NCDR-ACTION Registry Steering Committee, and VA CART Research and Publications Committee; has served on the data monitoring committees of Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi-Sankyo), and the Population Health Research Institute; has received honoraria from the American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Vice-Chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor-in-Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor-in-Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), K2P (Co-Chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today’s Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), and WebMD (CME steering committees); has served as Deputy Editor of Clinical Cardiology; has received research funding from Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi, Synaptic, and The Medicines Company; has received royalties from Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease); has served as site co-investigator for Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), and Svelte; served as a trustee of the American College of Cardiology; and has received unfunded research from FlowCo, Merck, Novo Nordisk, and Takeda. Dr. Balmes is the Physician Member of the California Air Resources Board. Dr. Brook has received an investigator-initiated grant from RB, Inc.; and has received support from NIH awards 2R01-ES019616 and 2R01-NR014484. Dr. Brauer has received grant support from the Health Effects Institute, the Canadian Institutes of Health Research, The Terry Fox Research Institute, and the Wellcome Trust. Dr. Hansel has received grant support from the NIH, EPA, NHLBI, National Institute of Environmental Health Sciences, COPD Foundation, and Boehringer Ingelheim; and has participated in advisory boards for GlaxoSmithKline, AstraZeneca, and Mylan. Dr. Hernandez has received research funding from American Regent, AstraZeneca, Boehringer Ingelheim, Merck, Novartis, and Verily; and has served as a consultant for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Merck, Novartis, and Relypsa. Dr. Hochman has received grant support from the NHLBI for the ISCHEMIA Trial, for which there were in-kind donations for participating sites from Abbott Vascular, Medtronic, Inc., St. Jude Medical, Inc., Volcano Corporation, Arbor Pharmaceuticals, AstraZeneca Pharmaceuticals, Merck Sharp & Dohme Corp., Omron Healthcare, Inc., and Amgen Inc; has received financial donations from Arbor Pharmaceuticals and AstraZeneca Pharmaceuticals; and has served as PI for the ZEDS (Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus) Study, supported by NIH/National Eye Institute. Dr. Kaufman has received grant support from the National Institutes of Health and the Environmental Protection Agency. Dr. Malik is supported by the NHLBI of the NIH under Award Number T32HL110837. Dr. Peel has received research funding from the NIH (1UM1HL134590 and R01ES023688). Dr. Rajagopalan has received research funding from the NIH; and has served as a consultant to Novo Nordisk, Takeda, GlaxoSmithKline, and AstraZeneca. Dr. Zhang’s research has been partly funded by the NIH, Underwriter’s Laboratory, and Natural Science Foundation of China (via Duke Kunshan University in China). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2020 American College of Cardiology Foundation. All rights reserved.)